ICU Medical (NASDAQ: ICUI) reported Q4 EPS of $2.11, $0.62 better than the analyst estimate of $1.49. Revenue for the quarter came in at $629.81 million versus the consensus estimate of $593.86 million.

Fiscal Year 2025 Guidance

For fiscal year 2025 the Company estimates GAAP net loss to be in the range of $(45) million to $(28) million and GAAP net loss per share estimated to be in the range of $(1.81) to $(1.11).

For the fiscal year 2025, excluding the potential impact from the Company's previously announced IV Solutions joint venture transaction, the Company expects adjusted EBITDA to be in the range of $395 million to $425 million, and adjusted EPS to be in the range of $6.55 to $7.25. The Company anticipates the IV Solutions joint venture will close during the second quarter of 2025 and, if so, is expected to reduce the 2025 adjusted EBITDA guidance by $15 million to $20 million and be neutral to adjusted EPS.

For earnings history and earnings-related data on ICU Medical (ICUI) click here.